Cabozantinib Not Superior to Prednisone for Pretreated mCRPC

Share this content:
When compared to prednisone, cabozantinib failed to improve overall survival of heavily pretreated patients with mCRPC.
When compared to prednisone, cabozantinib failed to improve overall survival of heavily pretreated patients with mCRPC.

When compared to prednisone, cabozantinib failed to improve overall survival of heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) who experienced disease progression after docetaxel and abiraterone acetate and/or enzalutamide, according to a study published in the Journal of Clinical Oncology.1

For this phase 3 COMET-1 study, investigators enrolled 1028 patients with progressive mCRPC after receipt of docetaxel and abiraterone and/or enzalutamide. Participants were randomly assigned 2:1 to receive cabozantinib 60 mg orally once daily or prednisone 5 mg orally twice daily.

Median overall survival was 11.0 months with cabozantinib, versus 9.8 months with prednisone (hazard ratio, 0.90; 95% CI, 0.76-1.06; P = .213), suggesting that the primary end point of overall survival was not met.

Researchers found, however, that 42% of patients who received cabozantinib achieved a bone scan response at week 12, versus 3% of those who had prednisone (P < .001). Radiographic progression-free survival favored cabozantinib (hazard ratio, 0.48; 95% CI, 0.40-0.57; P < .001).

RELATED: ADT Plus Radiotherapy Boosts Survival in Metastatic Prostate Cancer

Cabozantinib was associated with improvements in circulating tumor cell (CTC) conversion, bone biomarkers, and incidence of symptomatic skeletal events, but it was not associated with improved serum PSA outcomes.

Seventy-one percent of patients in the cabozantinib arm reported grade 3 to 4 adverse events, compared with 56% in the prednisone arm; 33% and 12% discontinued therapy, respectively.

Reference

1. Smith M, De Bono J, Sternberg C, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016 Jul 11. doi: 10.1200/JCO.2015.65.5597 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs